INDUSTRY SUPPORTED SESSIONS

​​Saturday, May 31, 2014 

12:00-13:30 - Francisco Grande Covian Hall ​


ELEVATED LDL: NOT ALWAYS FAMILIAL HYPERCHOLESTEROLEMIA 
3 MYSTERY CASES FOR YOU TO DIAGNOSE
Chair:     Prof. Emilio Ros, Spain
  • Case 1 
    Prof. Handrean Soran​, UK
  • Case 2
    Prof. Ornella Guardamagna​, Italy
  • Case 3
    Kees Hovingh, ​The Netherlands​


14:00-15:30 - Francisco Grande Covian Hall ​

​This educational symposium is supported by an educational grant from BASF, Danone​,
Raisio and Unilever​

DIET AT THE HEAR​T OF CVD PREVENTION  ​​

Chairs:             Alberico Catapano, Italy
                    John Chapman, France

14:00-14:05    Welcome & introduction 
                           Alberico Catapano, Italy
                           John Chapman, France​ 

14:05-14:35    Diet – the corner stone of cholesterol management
                           ​David Jenkins, ​Canada

14:35-14:40    Questions

14:40-14:55    Behaviour change is possible “small steps – big difference”
                           Louis Masana, Spain

14:55-15:05    Behaviour change is possible, behaviour change in practice
                           Helena Gylling, Finland

15:05-15:10    Questions

15:10-15:20    Introducing the E-learning tool
                           Simon Hackett, Pegasus

15:20-15:30    Summary & Close
                           Alberico Catapano, Italy
                           John Chapman, France

16:00 - 17:30 - Francisco Grande Covian Hall 

Aegrion.jpg

BRIDGING THE TREATMENT GAP IN HoFH

Chairs:               Kausik R​ay, UK
                            Pedro Mata​​​, Spain 

​16:00-16:05     Welcome 
                     Kausik R​ay, UK
                            Pedro Mata​​​, Spain

16:05-16:25     Identifying the target   - Who are we treating and to what target? 
                            Marina Cuchel, USA

16:25-16:45    When to intervene - The urgency to treat 
                           Gil Thompson, UK

16:45-17:15    Tools of the trade - New treatment options in HoFH 
                           Dirk Blom, South Africa

17:15-17:30    Question and answers
                           Kausik R​ay, UK
                           Pedro Mata​​​, Spain 

Sunday, June 1, 2014 

​13:00-14:30 - Manuel de Oya Hall 

Accredited Educational Program​

Astrazeneca Logo for website.jpg

MIXED HYPERLIPIDEMI AND TRIGLYCERIDES IN CARDIOVASCULAR PREVENTION​

Chairs:           Rafael Carmena, Spain

                        Olov Wiklund, Sweden

  •                Triglycerides, cholesterol and HDL in CVD  –  lessons from genetics​
                   Børge Nordestgaard, Denmark
  •                Mechanistic bases for the origin and therapy of elevated triglycerides and mixed hyperlipidemia
                   Gerald Watts, Australia
  •                Mixed hyperlipidemia and triglycerides in current guidelines for treatment
                   Olov Wiklund, Sweden
  •                Concluding remarks and discussion
                   Rafael Carmena, Spain

14:00 - 15:00 - Francisco Grande Covian Hall 

Rottapharm.jpg

APPROACH TO MODERATE CARDIOMETABOLIC RISK SUBJECTS: WHICH ROLE FOR NUTRACEUTICALS?​

Chairs:          Alberico Catapano, Ital​y
                        Gerd Assmann, Germany​

Panel:          Individuals at moderate cardiovascular risk: strategic considerations
                       Gerd Assmann, Germany

                       How to manage moderate cardiometabolic risk subjects?
                       B. Trimarco, Italy

                       Effect of a nutraceutical product on lipid profile in hypercholesterolemic subjects: a meta-
                       analysis
                       Jesús Millán Núñez-Cortés​, Spain

17:00-18:30 - Francisco Grande Covian Hall 


COMPREHENSIVE LIPID MANAGEMENT:  A TREATMENT PARADIGM FOR OPTIMAL CARDIOVASCULAR RISK REDUCTION​​

Chair:                 Alberico Catapano, Ital​y

17:00–17:05     Chair Welcome and Opening Remarks 
                             Alberico Catapano, Ital​y

17:05–17:20    LDL Insights into Genetics and Epidemiology
                            Chris Packard, UK

17:20–17:25   Question & Answer Session

17:25–17:40   Bringing More Patients to Their Individual Treatment Goal
                          Philip Barter, Australia

17:40–17:45  Question & Answer Session  Faculty

17:45–18:00  Outcomes Studies in LDL-C Reduction: What More can be Achieved?
                          Ulrich Laufs, Germany

18:00–18:05  Question & Answer Session

18:05–18:25  Round Table Panel Discussion
                          Alberico Catapano, Ital​y
                          Chris PackardUK
                          Philip Barter, Australia
                          Ulrich LaufsGermany

18:25–18:30  Closing Comments
                          Alberico Catapano, Ital​y​​

17:00-17:45 - Manuel de Oya Hall 

Diadexus.jpg

MEET THE SPEAKER SESSION: ​Lp-PLA2: Risk Marker or Risk Factor?
Presenter: Michelle O’Donoghue​, Boston, USA​ 

17:00-17:45 - Amador Schuller Hall

Elsevier Logo.jpg

REVIEWERS’ WORKSHOP​

Hosted by: Dr​. Sarah Leigh
A presentation followed by an open question and answer session about the aspects of the peer review process.

If you are interested in becoming a reviewer or if you already review but feel that you would like some more guidance please join us!​

Monday, June 2,​ 2014 ​

13.00 – 14.30​ - Manuel de Oya Hall 

Amgen_Cardiovascular_Logo_RGB_NEW.jpg 

ADDRESSING THE NEEDS OF HIGH-RISK PATIENTS IN HYPERLIPIDEMIA M​ANA​GEMENT:
THE THERAPEUTIC HORIZON

Chairs:             Alberico Catapano, Italy 
                           Luis Masana, Spain

13:00–13:05    Welcome and introduction
                           Alberico Catapano, Italy 
                           Luis Masana, Spain

13:05–13:25  Hyperlipidemia management in high-risk patients: what we have and what
                           we need
                           John Kastelein, The Netherlands

13:25–13:55   Management of hyperlipidemia: what does the future hold?
                           Evan Stein, USA

13:55–14:25   Monoclon​al antibodies targeting PCSK9: gaining insight into their potential in clinical practice          
                           Alberico Catapano, Italy and Evan Stein, USA

14:25–14:30    Final Q&A and meeting close
                           Alberico Catapano, Italy 
                           Luis Masana, Spain​

Monday, June 2, 2014 

14:00-15:00 - Amador Schuller Hall​

Chiesi Logo.jpg 

FROM CONCEPT TO REALITY – A NEW DAWN IN GENE THERAPY FOR SEVERE LPLD

Chair:                  Prof. Maurizio R Averna, Italy

14:00-14:05 ​    ​ Welcome, introductions and opening remarks
                             Prof. Maurizio R Averna, Italy, Chair

14:05-14:25      Genetic and clinical characteristics of lipoprotein lipase deficiency (LPLD)
           Prof. Maurizio R Averna, Italy
14:25–14:45     Gene therapy for severe LPLD – clinical perspective and clinical challenges
                   Dr. Daniel Gaudet, Canada
14:45–14:55     Questions and answers
                   Prof. Maurizio R Averna, Italy and Dr. Daniel Gaudet, Canada
14:55–15:00     Closing remarks
                   Prof. Maurizio R Averna, Italy


​17:00 - 18:30 - Francisco Grande Covian ​Hall 

logo Sanofi-Regeneron.jpg
PCSK9 – FROM GENOMICS TO CUSTOMIZED LIPID LOWERING APPROACHES

Chair:               Prof. John J. Kastelein​, The Netherlands
17:00-17:05   Introduction
                          Prof. John J. Kastelein​, The Netherlands
17:05-17:25   From genomic revolution to emerging therapies
                          Prof. Gilles Lambert, France
17:25-17:45   Monoclonal antibodies - an innovative approach for PCSK9 inhibition
                          Prof. Alberico Catapano, Italy
​17:45-18:05   PCSK9 monoclonal antibodies for a tailored LDL-C lowering approach
                          Prof. Michel Farnier, France
18:05-18:25   Panel discussion
                          Prof. John J. Kastelein​, The Netherlands
                          Prof. Gilles Lambert, France
                          Prof. Alberico CatapanoItaly
                          Prof. Michel Farnier, France
18:25-18:30   Closing Remarks
                          Prof. John J. Kastelein​, The Netherlands

17:00-17:45 - Amador Schuller Hall​​


ALL STATINS CAUSE DIABETES? A DEBATE

Chair:                 Prof. Toru Kita, Japan

17:00-17:10      Chair’s welcome and introduction
                             Prof. Toru Kita, Japan

17:10​-17:20     All statins cause diabetes? The case For the motion 
                            Prof. Kausik Ray, UK

17:20-17:30     All statins cause diabetes? The case Against the motion
                            Prof. Lluis Masana, Spain
17:30-17:35     Rebuttal
                            Prof. Kausik RayUK
17:35-17:40     Rebuttal
                            Prof. Lluis MasanaSpain
17:40-17:45     Chair’s summary and close​
                      Prof. Toru Kita, Japan


​​

Keep Me Updated